EnhydrisPECorp
Contributor since: 2012
Company: Daily Biotech
Articles
Sunesis Pharmaceuticals, Inc. Craters On Negative VALOR Data. Stock Is Now A Terminal Short
Solid Management And Robust Balance Sheet Point To Large Upside For Prothena
Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side
MannKind Corp. And The Folly Of Cult Biotech Stocks
Enanta Pharmaceuticals Is Simply Too Cheap To Ignore
Evidence For And Against A Biotech Bubble
Galena Biopharma: The Legal Stakes Are Rising
Clearing The Air On Galena's Legal Woes
Did Galena Biopharma Mislead Investors And Patients About NeuVax?
Prana Biotechnology And MannKind Corp.: Bad News Obeys Its Own Special Laws
A Deeper Look At The Galena Biopharma Controversy
Chelsea Therapeutics: The Good, The Bad And The Ugly
Ariad Pharmaceuticals: Long-Term Prospects Of The Biotech Beauty Contest
Dear Healthcare Investors: The Correction, It's Here
Vringo: How To Lose At Winning
Is The Healthcare Sector Pulling Back Or Crashing?
Why MannKind Is My 2014 Short Pick In Healthcare
The Next Home Run In Healthcare
Buyout Picks In Healthcare For 2014
Healthcare Picks By Drug Type In 2014
Healthcare Stocks To Avoid This Year
Positioning For 2014 In The Health Care Sector
3 Biotechs That Could Double In 2014
Proof Positive That Vringo Is Dead Money
The Curious Case Of Questcor Pharmaceuticals
What's Next For ImmunoCellular?
Bad News Biotechs Of 2013
Will Amarin And Arena See Better Sales In 2014?
2014 Could Be A Big Year For Inovio, Merrimack, And NeoStem
Arrowhead Research Corp: What Am I Missing?
ImmunoCellular Is A High Risk, High Reward Biopharma
Vringo: Belief And Seeing Are Both Often Wrong